Aspen Pharmacare Long-Term Investments 2017-2025 | APNHY

Aspen Pharmacare long-term investments from 2017 to 2025. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Aspen Pharmacare Annual Long-Term Investments
(Millions of US $)
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Aspen Pharmacare Quarterly Long-Term Investments
(Millions of US $)
2025-06-30
2024-06-30
2023-12-31
2023-06-30
2022-12-31
2022-06-30
2021-12-31
2021-06-30
2020-12-31
2020-06-30
2019-06-30
2018-12-31
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2016-06-30
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $3.708B $2.388B
Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $35.437B 10.97
BridgeBio Pharma (BBIO) United States $14.460B 0.00
Dr Reddy's Laboratories (RDY) India $11.109B 17.29
Supernus Pharmaceuticals (SUPN) United States $2.918B 22.33
Bausch Health Cos (BHC) Canada $2.086B 1.50
Taysha Gene Therapies (TSHA) United States $1.290B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.924B 7.28
Personalis (PSNL) United States $0.630B 0.00
Assembly Biosciences (ASMB) United States $0.451B 0.00
Sol-Gel Technologies (SLGL) Israel $0.210B 0.00
Metagenomi Therapeutics (MGX) United States $0.052B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00